Barak Azmon

Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel.

Ophthalmic Imaging Systems, Inc. manufactures ophthalmic digital imaging systems. Its principal activity is to design, develop, manufacture and market digital imaging system, image enhancement and analysis software and related products and services used by the practitioners in the ocular healthcare field. The current flagship product in the Group's angiography line is its digital imaging systems. Its products include WinStation systems, Digital Fundus Imager, Digital Slit Lamp Imager and Slit Lamps. Retina specialists and general ophthalmologists use the WinStation systems. The company was founded on July 14, 1986 and is headquartered in Sacramento, CA.

Tel-Aviv Sourasky Medical Center operates as a medical center. Tel Aviv Sourasky Medical Center provides progressive full-service healthcare treatment and research institutions in Israel. The Medical Center draws patients from throughout the world for specialty care and routine procedures through the medical tourism program, designed specifically for the needs of international patients. The center was founded in 1963 and is headquartered in Tel Aviv, Israel.

Part of Notal Vision Ltd., Notal Vision, Inc. develops ophthalmic diagnostic devices. The private company is based in Manassas, VA. The company was founded by Barak Azmon. The CEO is Kester Nahen.

TearLab Corporation, Inc. engages in the development and marketing of a tear testing platform. Its primary product, the TearLab Osmolarity System, enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. It measures tear film osmolarity for the diagnosis of dry eye disease. The company was founded by Benjamin D. Sullivan in 1996 and is headquartered in Escondido, CA.